Immunogen Inc
IMGN
IMGN was delisted on the 9th of February, 2024.
266 hedge funds and large institutions have $4.24B invested in Immunogen Inc in 2023 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 67 increasing their positions, 72 reducing their positions, and 25 closing their positions.
426% more capital invested
Capital invested by funds: $805M → $4.24B (+$3.43B)
304% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 25
93% more call options, than puts
Call options by funds: $69.3M | Put options by funds: $35.8M
40% more funds holding
Funds holding: 190 → 266 (+76)
7% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$114M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$103M |
| 3 |
D.E. Shaw & Co
New York
|
+$74.2M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$71.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$70M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$231M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$201M |
| 3 |
State Street
Boston,
Massachusetts
|
-$108M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
-$48M |
| 5 |
Morgan Stanley
New York
|
-$47M |
IMGN Hedge Fund Activity: Q2 2023 in Review
266 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q2 2023, worth a combined $4.24B — up 426% from $805M a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new IMGN positions and 25 closed out — a net gain of 76 holders — while 67 added to existing stakes and 72 trimmed.
The largest buyer was Redmile Group, adding an estimated $114M. The largest seller was RA Capital Management, cutting an estimated $231M.
- 266 institutional investors held Immunogen Inc (IMGN) as of Q2 2023, up from 190 in Q1 2023.
- Funds reported $4.24B of Immunogen Inc stock for Q2 2023, up 426% quarter-over-quarter.
- 101 funds opened new Immunogen Inc positions in Q2 2023 and 25 closed out, a net change of +76 holders.
- The largest Immunogen Inc buyer in Q2 2023 was Redmile Group, an estimated $114M added.
- The largest Immunogen Inc seller in Q2 2023 was RA Capital Management, an estimated $231M sold.
Based on aggregated 13F filings for Q2 2023.